As the coronavirus pandemic continues to affect millions of Americans in the U.S. alone, more than two million people have been infected and over 100,000 have died researchers are urgently seeking treatment options for COVID-19, the illness caused by the novel coronavirus
Induced Pluripotent Stem Cells Forming an Emerging Market WELLESLEY, Mass.-June 16, 2020- (Newswire.com) The global market for induced pluripotent stem cells (iPSCs), should reach $3.8 billion, growing 9.2% annually, according to the latest report by BCC Research, Induced Pluripotent Stem Cells: Global Markets. iPSCs are reprogrammed cells from a patients body and are not harvested from embryos, thus avoiding the ethical debates associated with embryonic stem cells.
DUBLIN, June 18, 2020 /PRNewswire/ -- The "Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography" report has been added to ResearchAndMarkets.com's offering. The stem cell therapy market was valued at US$ 1,534.55 million in 2019 and is estimated to reach US$ 5,129.66 million by 2027; it is expected to grow at a CAGR of 16.7% from 2020 to 2027. The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market
Mesenchymal stem cells are the adult stem cells. Mesenchymal stem cells are of various types such as monocytes, adipocytes, osteocytes and chondrocytes.
Los Angeles, United State: Complete study of the global Human Primary Cells market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Human Primary Cells industry
Residents of the Caribbean know that between a tropical storm and a major hurricane, there is a world of difference. Both bring rain and winds, but weathering and surviving a hurricane requires much greater response and resilience
ST. LOUIS, June 18, 2020 /PRNewswire/ -- OpenCell Technologies, an R&D-stage biomedical venture, has announced the hiring of Kevin Gutshall as CEO. Kevin leaves his role as MilliporeSigma's director of life science business development and M&A focusing on the cell and gene therapy business unit, to join OpenCell and lead its efforts to translate and commercialize its core technology platform, POROS.
Our company has built a platform to produce high-quality cells and tissues for regenerative medicine. That pursuit involves multiple disciplines, which means everyone here is an expert in a different language. Some of us are fluent in stem-cell biology, others in optical engineering, others in machine learning.
As you were browsing http://www.streetinsider.com something about your browser made us think you were a bot. If you are interested in http://www.streetinsider.com content, APIs are available
Global Precision Medicine market is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. This analysis provides an examination of various market segments that are relied upon to observe the fastest development amid the estimated forecast frame. The report encompasses market definition, currency and pricing, market segmentation, market overview, premium insights, key insights and company profile of the key market players.
Recent Comments